Boston Trust Walden Corp Has $41.99 Million Stock Holdings in Corcept Therapeutics Incorporated $CORT

Boston Trust Walden Corp trimmed its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 572,072 shares of the biotechnology company’s stock after selling 12,728 shares during the quarter. Boston Trust Walden Corp owned about 0.54% of Corcept Therapeutics worth $41,990,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. TD Asset Management Inc acquired a new position in shares of Corcept Therapeutics during the second quarter valued at about $60,179,000. Jupiter Asset Management Ltd. grew its holdings in shares of Corcept Therapeutics by 8,176.0% during the first quarter. Jupiter Asset Management Ltd. now owns 603,903 shares of the biotechnology company’s stock valued at $68,978,000 after buying an additional 596,606 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Corcept Therapeutics by 76.5% during the first quarter. Invesco Ltd. now owns 1,246,234 shares of the biotechnology company’s stock valued at $142,345,000 after buying an additional 540,101 shares during the last quarter. Nuveen LLC acquired a new position in shares of Corcept Therapeutics during the first quarter valued at about $35,580,000. Finally, Driehaus Capital Management LLC acquired a new position in shares of Corcept Therapeutics during the first quarter valued at about $29,657,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $72.12 on Wednesday. The firm has a market cap of $7.60 billion, a price-to-earnings ratio of 63.82 and a beta of 0.46. Corcept Therapeutics Incorporated has a 52 week low of $42.01 and a 52 week high of $117.33. The firm’s 50-day simple moving average is $75.60 and its two-hundred day simple moving average is $73.42.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06. The company had revenue of $194.43 million for the quarter, compared to analyst estimates of $199.40 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The company’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Corcept Therapeutics has set its FY 2025 guidance at EPS. Analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Insider Activity

In related news, insider William Guyer sold 35,007 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $71.77, for a total transaction of $2,512,452.39. Following the completion of the transaction, the insider owned 5,487 shares of the company’s stock, valued at approximately $393,801.99. The trade was a 86.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph Douglas Lyon sold 5,823 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $67.51, for a total transaction of $393,110.73. Following the completion of the transaction, the insider directly owned 10,066 shares of the company’s stock, valued at approximately $679,555.66. This represents a 36.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 304,610 shares of company stock worth $22,713,516 in the last three months. Insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Piper Sandler reduced their price objective on shares of Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating for the company in a report on Friday, August 1st. Canaccord Genuity Group reiterated a “buy” rating and set a $140.00 price objective on shares of Corcept Therapeutics in a report on Thursday, September 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Wednesday, October 8th. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 1st. Finally, HC Wainwright restated a “buy” rating and set a $145.00 price target on shares of Corcept Therapeutics in a report on Friday, October 10th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $135.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.